Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NB 01

Drug Profile

NB 01

Alternative Names: DA-9801; NB-01

Latest Information Update: 08 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dong-A Pharmaceutical
  • Developer NeuroBo Pharmaceuticals
  • Class Neuroprotectants; Phytotherapies
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic neuropathies

Most Recent Events

  • 02 Aug 2023 NB 01 licensed to MThera Pharma worldwide for the treatment of Diabetic neuropathy
  • 25 Apr 2023 NB 01 is available for licensing as of 25 Apr 2023. https://www.sec.gov/ix?doc=/Archives/edgar/data/1638287/000155837023005127/nrbo-20221231x10k.htm
  • 31 Dec 2022 NeuroBo Pharmaceuticals has patent protection for NB 01 in USA, Brazil, Canada, China, the European Patent Convention, India, Japan, Mexico, the Republic of Korea, and Russia
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top